CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 90 enrolled
Drug / intervention
regadenosondrug
Likely dose
regadenoson 400 μgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01842035
NCT01842035N/ACompleted
CompareCT.gov

Heart Rate Response to Regadenoson and Sudden Cardiac Death

University of Alabama at Birmingham·interventional·Posted Apr 29, 2013·Updated Oct 18, 2022

In Brief

A clinical study evaluating regadenoson for Left Ventricular Systolic Dysfunction and Sudden Cardiac Death. Completed, enrolled 90 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether a blunted heart rate response to regadenoson is an independent predictor of sudden cardiac death.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeft Ventricular Systolic Dysfunction, Sudden Cardiac Death
CountriesUnited States
CollaboratorsAstellas Scientific & Medical Affairs, Inc.

Timeline

N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedApr 29, 2013
Enrollment StartFeb 1, 2013
Primary CompletionApr 1, 2020
Study CompletionJul 1, 2022
TodayJul 2, 2026
Enrollment to primary: 7.2 yearsPosted 13.2 years ago

Interventions

regadenosondrug

Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.